There was a time Moreau (CEO) and Williams (former CSO) ...told shareholders on BioPub and elsewhere in the web world that the Repurposed Drugs Strategy had a better than 60% chance of success at Phase II of the clinical trial process. However, the fine print for the Repurposed Drugs Strategy wasn't transparent enough to point out the fact that the Phase II studies by Algernon (COVID-19 | IPF | Chronic Cough) needed to be powered for statistical significance to come anywhere near close to 60% success. We are now in do over territory and out the gate I’m hoping Algernon has a better than 60% of a Nasdaq uplist. Surely, the decision is now out of management's hands and that’s probably a good thing.